Novel therapeutic vaccine: Granulysin and new DNA vaccine against Tuberculosis

• Published in: Human vaccines Vol. 7; no. sup1; pp. 60 - 67
• Main Authors: Okada, Masaji, Kita, Yoko, Nakajima, Toshihiro, Kanamaru, Noriko, Hashimoto, Satomi, Nagasawa, Tetsuji, Kaneda, Yasufumi, Yoshida, Shigeto, Nishida, Yasuko, Nakatani, Hitoshi, Takao, Kyoko, Kishigami, Chie, Nishimatsu, Shiho, Sekine, Yuki, Inoue, Yoshikazu, Matsumoto, Makoto, McMurray, David N., De la Cruz, E.C., Tan, E.V., Abalos, R.M., Burgos, J.A., Saunderson, Paul, Sakatani, Mitsunori
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 01.01.2011
• Subjects: Adjuvants, Immunologic - administration & dosage; Animals; Antigens, Differentiation, T-Lymphocyte - administration & dosage; Bacterial Proteins - genetics; Bacterial Proteins - immunology; Binding; Biology; Bioscience; Calcium; Cancer; Cell; Chaperonin 60 - genetics; Chaperonin 60 - immunology; Cycle; Disease Models, Animal; Humans; Immunotherapy - methods; Interleukin-12 - genetics; Landes; Macaca fascicularis; Organogenesis; Primate Diseases - microbiology; Primate Diseases - therapy; Proteins; Rodent Diseases - microbiology; Rodent Diseases - therapy; Survival Analysis; Treatment Outcome; Tuberculosis Vaccines - genetics; Tuberculosis Vaccines - immunology; Tuberculosis, Multidrug-Resistant - immunology; Tuberculosis, Multidrug-Resistant - therapy; Vaccines, DNA - genetics; Vaccines, DNA - immunology
• ISSN: 1554-8600; 2164-5515; 1554-8619; 2164-554X
• DOI: 10.4161/hv.7.0.14563

[Purpose] Multi-drug resistant (MDR) Mycobacterium Tuberculosis (M.TB) is a big problem in the world. We have developed novel TB therapeutic vaccines. [Methods and Results] DNA vaccine expressing mycobacterial heat shock protein 65 and IL-12 was delivered by the hemagglutinating virus of Japan (HVJ)-envelope. M. TB, MDR-TB or extremenly drug resistant (XDR-TB) was injected i.v. into DBA/1 mice, and treated with the vaccine three times. This HVJ-E/Hsp65DNA+IL-12DNA vaccine provided strong therapeutic efficacy against MDR-TB and XDR-TB (prolongation of survival time and the decrease in the number of TB) in mice. Therapeutic effect of this vaccine on TB infection was also demonstrated in chronic TB infection murine model using aerosol infection intratracheally. On the other hand, granulysin protein produced from CTL has lethal activity against TB. Granulysin protein vaccine also exerted strong therapeutic effect. Furthermore, we extended our studies to monkey model, which is currently the best animal model of human TB. Hsp65DNA+IL-12 DNA vaccine exerted strong therapeutic efficacy (100% survival and augmentation of immune responses) in the TB-infected monkeys. In contrast, the survival of the saline control group was 60% at 16 week post-challenge. HVJ-Envelope/HSP65 DNA+IL-12 DNA vaccine increased the body weight of TB-infected monkeys, improved the erythrocyte sedimentation rate, and augmentated the immune responses (proliferation of PBL and IL-2 production). The enhancement of IL-2 production from monkeys treated with this vaccine was correlated with the therapeutic efficacy of the vaccine. [Conclusion] These data indicate that novel vaccines might be useful against TB including XDR-TB and MDR-TB for human therapeutic clinical trials.